NCT02362958
Breast Cancer Type: HER2+
Hormone Mutations: ER+, PR+
Other Mutations:
Breast Cancer Tissue:
Recruitment Status: Recruiting
Phase 2
Drug Category: Tyrosine-Kinase Inhibitor, Chemotherapy
Key Eligibility Criteria:
Gender: Female
Age: 18 Years to 65 Years (Adult)
Location of Metastases:
Additional Notes:
Exclusions:
https://ClinicalTrials.gov/show/NCT02362958